This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Sangamo Therapeutics, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Mohammad Samie: Innovator in Genetic Modulation
Introduction
Mohammad Samie is a notable inventor based in Richmond, CA (US). He has made significant contributions to the field of genetic research, particularly in the modulation of gene expression related to neurodegenerative diseases.
Latest Patents
Samie holds a patent titled "Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof." This patent provides compositions and methods for modulating the transcription of mutant C9orf72 gene alleles in patients suffering from C9orf72-related diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). He has 1 patent to his name.
Career Highlights
Currently, Mohammad Samie is associated with Sangamo Therapeutics, Inc., a company focused on genomic medicine. His work at Sangamo Therapeutics involves innovative approaches to gene therapy and genetic modulation.
Collaborations
Samie collaborates with talented professionals in his field, including Amrutha Pattamatta and Joseph F Nabhan. Their combined expertise contributes to advancing research in genetic therapies.
Conclusion
Mohammad Samie's work in genetic modulation represents a significant advancement in the treatment of neurodegenerative diseases. His innovative approaches and collaborations continue to pave the way for future breakthroughs in this critical area of research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile